This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Celanese: Analysts' Upgrades, Downgrades

Stocks in this article: AMGN CE CELG


Amgen (AMGN - Get Report) rated new Buy at Stifel Nicolaus. $68 price target. Company has the only major new product among its peers.

Celanese (CE - Get Report) upgraded at Citigroup from Hold to Buy. $35 price target. Company is growing in China, which should also help keep costs down.

Celgene (CELG - Get Report) rated new Buy at Stifel Nicolaus. $71 price target. Company has superior growth prospects.

Gilead Sciences (GILD - Get Report) rated new Hold at Stifel Nicolaus. Valuation call, as the company is facing patent expirations.

Idexx Laboratories (IDXX - Get Report) rated new Market Perform at Leerink. Stock is already pricing in the company's organic growth potential.

Skilled Healthcare Group (SKH - Get Report) upgraded at Credit Suisse to Neutral from Underperform as the company agreed to a $50 million settlement in the Lavender case. The settlement was significantly lower than the Street's expectation, Credit Suisse said. Price target increased to $5 from $2.

Teva Pharmaceutical (TEVA - Get Report) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $65 price target. Effexor XR launch was strong and the company should post better earnings in the second half of 2010.

Tellabs (TLAB) downgraded at Soleil from Buy to Hold. $8 price target. Estimates also cut, as the company is losing market share at Soleil.

Valspar (VAL) was downgraded at Citigroup from Buy to Hold. $32 price target. Paint sales tailed off toward the end of summer, as the housing market soured.


Altera (ALTR) estimates, target increased through 2011 at Citigroup. Company boosted guidance at its midquarter update. Buy rating and new $36 price target.

Arris (ARRS) estimates, target lowered at UBS. Estimates cut through 2011. Cable CapEx spending could be slowing down, along with the broader economy. Neutral rating and new $9 price target.

Allegheny Energy (AYE) numbers boosted at Citigroup. Shares of AYE now seen reaching $24, according to Citigroup. Estimates also upped, as the company is cutting costs and should see higher regulated earnings. Hold rating.

Coca-Cola Enterprises (CCE) numbers raised at UBS. Shares of CCE now seen reaching $34, according to UBS. Estimates also increased, to match the company's new guidance. Buy rating.

Chesapeake Midstream Partners (CHKM) estimates cut at Barclays. 2011 EPS estimate lowered to $1.51, 2010 held at $1.05. Chesapeake Midstream reported second-quarter results in line, Barclays said. Maintain Overweight rating and $26 target.

Hasbro (HAS) target upped to $52 at Keybanc. Company held an upbeat investor meeting, and the Hub channel remains on track for launch. Buy rating.

Las Vegas Sands (LVS) numbers raised at JP Morgan. Shares of LVS now seen reaching $36, according to JP Morgan. Estimates also increased, given better results in Singapore. Overweight rating.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.83 -27.26 -1.33%
NASDAQ 4,684.0540 -87.7090 -1.84%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs